RT Journal Article
SR Electronic
T1 Safety and Survival Outcomes of <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior <sup>223</sup>Ra treatment: The RALU Study
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 574
OP 578
DO 10.2967/jnumed.122.264456
VO 64
IS 4
A1 Rahbar, Kambiz
A1 Essler, Markus
A1 Pabst, Kim M.
A1 Eiber, Matthias
A1 Fougère, Christian la
A1 Prasad, Vikas
A1 Rassek, Philipp
A1 Hasa, Ergela
A1 Dittmann, Helmut
A1 Bundschuh, Ralph A.
A1 Fendler, Wolfgang P.
A1 Kurtinecz, Milena
A1 Schmall, Anja
A1 Verholen, Frank
A1 Sartor, Oliver
YR 2023
UL http://jnm.snmjournals.org/content/64/4/574.abstract
AB The radium lutetium (RALU) study evaluated the feasibility of sequential α- and β-emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer. Methods: This preplanned interim retrospective analysis investigated safety and survival outcomes with 177Lu-PSMA in patients treated with prior 223Ra. Results: Forty-nine patients were evaluated. Patients received a median of 6 223Ra injections; 59% of patients received at least 4 177Lu-PSMA cycles. Most (69%) patients received at least 4 life-prolonging therapies before 177Lu-PSMA. Common Terminology Criteria for Adverse Events grade 3–4 treatment-emergent adverse events during 177Lu-PSMA therapy and a 30-d follow-up period included anemia (18%) and thrombocytopenia (2%). Median overall survival was 12.6 mo (95% CI, 8.8–16.1 mo) and 31.4 mo (95% CI, 25.7–37.6 mo) from starting 177Lu-PSMA or 223Ra, respectively. Conclusion: 177Lu-PSMA treatment was well tolerated in patients who had received prior 223Ra. 223Ra use before 177Lu-PSMA is feasible and can be considered for future assessment of the optimal treatment sequence.